Pyxis Oncology appoints Thomas Civik as permanent CEO and Chairman; Flavin becomes Lead Independent Director

Pyxis Oncology, Inc.

Civik, interim CEO since Feb 2026, named permanent CEO and Chairman effective Sept 4, 2026; Flavin transitions to Lead Independent Director.
New CEO package: $710k base salary, 60% target bonus, $100k sign-on bonus, and option for 2,503,050 shares vesting over 4 years.
Board member Santhosh Palani resigned Sept 4, 2026; board reduced from 8 to 7 members, with his unvested equity accelerated.
Company expects updated MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC in Fall 2026 and Phase 1/2 combo data with pembrolizumab in Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.